Skip to Content
You are currently on the new version of our website. Access the old version .
NeurogliaNeuroglia
  • Review
  • Open Access

13 November 2026

33 Pages

Extracellular Vesicles in Glioma: From Tumor Microenvironment Reprogramming to Liquid Biopsy and Therapeutic Translation

,
,
,
,
,
and
1
Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA
2
Department of Neurological Surgery, Albert Einstein College of Medicine, Bronx, NY 10461, USA
3
Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran
4
School of Medicine, Wayne State University, Detroit, MI 48201, USA
This article belongs to the Special Issue Glial Regulation in Neurooncology

Abstract

Gliomas remain refractory to contemporary neurosurgical and adjuvant therapies due to diffuse infiltration, immune evasion, and rapid development of therapeutic resistance. Extracellular vesicles (EVs), lipid-encapsulated substrates of various sizes that carry nucleic acid or proteins, are now recognized as central regulators of tumor–immune crosstalk and a potential unifying mechanism linking microenvironmental reprogramming with disease progression. Glioma-derived EVs function as active signaling platforms that remodel the tumor microenvironment. EV cargo—including PD-L1, TGF-β, and regulatory microRNAs—suppresses cytotoxic T-cell function, promotes M2 macrophage polarization, and impairs dendritic cell antigen presentation, collectively reinforcing an immunosuppressive niche. Additionally, EV-mediated transfer of resistance-associated cargo contributes to chemoresistance and radioresistance, representing key paracrine mechanisms of treatment failure. EV-associated nucleic acids specifically have enabled detection of alterations such as EGFRvIII, IDH1 mutations, and MGMT promoter methylation in early clinical studies. These findings support EV-based liquid biopsy as a promising approach for minimally invasive molecular characterization and disease monitoring. However, most mechanistic and therapeutic evidence remains preclinical, while clinical studies are limited by small cohorts, heterogeneous EV isolation and characterization methods, and a lack of prospective validation. Ultimately, EVs represent a biologically important interface between glioma biology and the immune microenvironment, with emerging applications in disease monitoring and therapeutic development. Prospective validation and technical standardization remain essential to enable clinical translation.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.